Literature DB >> 12581179

Modulatory action of acetylcholine on striatal neurons: microiontophoretic study in awake, unrestrained rats.

François Windels1, Eugene A Kiyatkin.   

Abstract

Cholinergic interneurons innervate virtually all medium spiny striatal cells, but the relevance of this input in regulating the activity and afferent responsiveness of these cells remains unclear. Studies in anaesthetized animals and slice preparations have shown that iontophoretic acetylcholine (ACh) either weakly excites or inhibits striatal neurons. These differential responses may reflect cholinergic receptor heterogeneity but may be also related to the different activity states of recorded units and different afferent inputs specific in each preparation. Single-unit recording was combined with iontophoresis in awake, unrestrained rats to examine the effects of ACh and selective muscarinic (oxotremorine M or Oxo-M) and nicotinic agonists (nicotine or NIC) on dorsal and ventral striatal neurons. These effects were tested on naturally silent, spontaneously active and glutamate-stimulated units. We found that iontophoretic ACh primarily inhibited spontaneously active and glutamate-stimulated units; the direction of the ACh response, however, was dependent on the firing rate. The effects of ACh were generally mimicked by Oxo-M and, surprisingly, by NIC, which is known to excite units in most central structures, including striatal neurons in anaesthetized preparation. Given that NIC receptors are absent on striatal cells but located primarily on dopamine terminals, we assessed the effects of NIC after complete blockade of dopamine receptors induced by systemic administration of a mixture of D1 and D2 antagonists. During dopamine receptor blockade the number of NIC-induced inhibitions dramatically decreased and NIC had mainly excitatory effects on striatal neurons. Thus, our data suggest that under physiologically relevant conditions ACh acts as a state-dependent neuromodulator, and its action involves not only postsynaptic but also presynaptic cholinoreceptors located on dopamine- and glutamate-containing terminals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12581179     DOI: 10.1046/j.1460-9568.2003.02492.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  7 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Reciprocal regulation of inhibitory synaptic transmission by nicotinic and muscarinic receptors in rat nucleus accumbens shell.

Authors:  Kiyofumi Yamamoto; Katsuko Ebihara; Noriaki Koshikawa; Masayuki Kobayashi
Journal:  J Physiol       Date:  2013-09-09       Impact factor: 5.182

3.  Single unit and population responses during inhibitory gating of striatal activity in freely moving rats.

Authors:  H C Cromwell; A Klein; R P Mears
Journal:  Neuroscience       Date:  2007-02-22       Impact factor: 3.590

4.  GABA, not glutamate, controls the activity of substantia nigra reticulata neurons in awake, unrestrained rats.

Authors:  François Windels; Eugene A Kiyatkin
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

Review 5.  Ovarian Hormones as a Source of Fluctuating Biological Vulnerability in Borderline Personality Disorder.

Authors:  Jessica R Peters; Tory A Eisenlohr-Moul
Journal:  Curr Psychiatry Rep       Date:  2019-10-17       Impact factor: 5.285

Review 6.  A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.

Authors:  Kenneth Grasing
Journal:  Behav Brain Res       Date:  2016-06-15       Impact factor: 3.332

7.  Action potential waveform variability limits multi-unit separation in freely behaving rats.

Authors:  Peter Stratton; Allen Cheung; Janet Wiles; Eugene Kiyatkin; Pankaj Sah; François Windels
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.